公开(公告)号：US11020396B2

公开(公告)日：2021-06-01

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: C07D403/14 ,  A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20190336502A1

公开(公告)日：2019-11-07

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  C07D417/14 ,  A61K31/551 ,  A61K31/437 ,  C07D471/04 ,  C07D403/14 ,  C07D413/14

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US11766434B2

公开(公告)日：2023-09-26

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US20220079942A1

公开(公告)日：2022-03-17

申请号：US17244171

申请日：2021-04-29

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.